Better Health for All

IQVIA's core business, providing advanced analytics, technology solutions, and contract research services to the life sciences industry, is fundamentally dedicated to improving health outcomes. Its entire service portfolio supports pharmaceutical, biotechnology, medical device, and healthcare companies in accelerating innovation and improving healthcare outcomes. The company generates no revenue from products with significant negative health impacts. IQVIA demonstrates exemplary inclusion practices in clinical trials, successfully increasing enrollment of Black participants by 1.7 times and Hispanic participants by 1.6 times compared to initial projections in an RSV vaccine trial, directly addressing health disparities in research.

The company has established a Global Public Health business unit, collaborating with over 75 clients worldwide, and supported governments in combating diseases like Marburg virus and mpox through vaccine effectiveness trials. It also partners with organizations like the Global Fund and (RED) for pandemic prevention and collaborates with the UK's National Health Service to improve lung cancer diagnosis. However, specific quantitative data on funding or expenditure for these health equity, preventative health, and global health crisis response initiatives is not provided, preventing their scoring against the rubric's thresholds. IQVIA's business model does not involve direct health products with inherent safety risks, pricing accessibility issues, or addiction potential for end-users. It also does not hold pharmaceutical patents, produce food products, or engage in direct health education or mental health initiatives as per the provided evidence. The company's operations do not generate significant health externalities.

Fair Pay & Worker Respect

In 2023, IQVIA conducted company-wide employee surveys with 80% of participants indicating they feel engaged.

The company's global workforce is diverse, with 61% female employees and women holding 52% of managerial positions. In the U.S., 47% of new hires identify as minorities. IQVIA maintains a zero-tolerance policy against child labor and forced labor, requiring suppliers to adhere to human rights principles. Compensation programs include salaries, bonuses, long-term incentives, and a range of wellness benefits.

Honest & Fair Business

IQVIA has a comprehensive Anti-Bribery and Anti-Corruption Corporate Policy that covers directors, officers, employees, contractors, and temporary staff.

This policy prohibits bribery, corruption, and facilitation payments, and the company is subject to the U.S. Foreign Corrupt Practices Act and the U.K. Bribery Act. Mandatory training on anti-bribery and anti-corruption is provided to all employees and contractors, with 97% of employees completing the annual Code of Conduct training in 2023. The company conducts an annual risk assessment and has an Ethics and Compliance Office that develops and implements the ethics and compliance program. The Chief Compliance Officer updates the Audit Committee of the Board of Directors quarterly. Mandatory due diligence procedures are in place for certain third-party intermediaries, and all commercial contracts require assurances from third-party organizations regarding ethical and legal operations.

Kind to Animals

IQVIA Holdings Inc. conducts pre-clinical studies on animals to assess product safety.

The company's Supplier Code of Conduct, updated in February 2024, states that animal testing should be minimized and alternatives used whenever possible, and that suppliers shall treat animals humanely, minimizing pain and stress. This indicates a commitment to reduction in principle but lacks measurable goals or accountability. In November 2025, 21 IQVIA team members visited a wildlife hospital to learn about rescue work and participate in snake enrichment, with interest expressed in future volunteering. The company also supports environmental and animal welfare organizations in Poland.

No War, No Weapons

IQVIA Holdings Inc. operates in healthcare and life sciences, focusing on improving healthcare outcomes and advancing medical research, with no involvement in arms manufacturing or military contracts.

The company's services are centered on clinical research, healthcare data analytics, and technology solutions, including the use of AI for a healthier world. In 2023, IQVIA disclosed $60,000 in lobbying expenditures, primarily for government contracting, data privacy proposals, and data-driven products and services.

Planet-Friendly Business

IQVIA has an SBTi-verified goal to achieve net-zero emissions by 2050

. The company has achieved a 27% reduction in Scope 1 and 2 greenhouse gas emissions compared to its 2019 baseline . Furthermore, 50% of its suppliers have either set or committed to setting science-based emission reduction targets . The company has also removed nearly 3 metric tons of single-use plastic from clinical trial test kits and avoided 384 metric tons of CO2 equivalent in lab freezer waste . All 17 of IQVIA's laboratories have achieved My Green Lab certification , with 47% certified at the highest level .

Safe & Smart Tech

IQVIA maintains a robust compliance program

, is well-placed to comply with emerging regulations like the EU AI Act , and actively supports the development of new health data management guidelines . The company has established a Center for Defensible AI and an AI Governance Council , employing procedures to evaluate high-risk AI activities for error, bias, and hallucinations . IQVIA holds ISO 27001 certification for its Patient Finder solution , a CE+ certificate for U.K. cloud operations , and its global data centers undergo annual SOC2 Type II attestation . The company is an industry leader in de-identifying data , rendering it non-identified while maintaining utility . No documented incidents of unauthorized data use are reported, and preventative measures include establishing private instances of large language models to protect proprietary content . IQVIA shares its expertise on de-identification methodologies with policymakers and regulators to avoid re-identification risk .

Zero Waste & Sustainable Products

IQVIA has implemented multiple waste reduction initiatives, including removing nearly 3 metric tons of single-use plastic outer packaging for clinical trial test kits in 2023/2024.

Its "Think Before You Ink" campaign achieved a 35% reduction in printed page volume since 2020. The company also extends the useful life of its computer fleet from three to five years and partners with Kits4Life to repurpose supplies. For hazardous waste, IQVIA is committed to proper management , provides training for employees handling biological and hazardous waste , and its largest labs are certified to ISO 14001:2015 and ISO 45001:2018. All 17 of IQVIA's laboratories are My Green Lab certified , with 47% certified to the highest level , and the company received the Race to Zero Leadership Award.